COMBINATION PHARMACEUTICAL COMPOSITIONS
0 Assignments
0 Petitions
Accused Products
Abstract
A modified release dosage product (5) comprises a plurality of minicapsules or minispheres (1, 2) containing nimodipine, and a plurality of minicapsules or minispheres (3), (4) containing tacrolimus. There are uncoated minicapsules or minispheres (1) encapsulating micronized nimodipine for immediate release and a controlled release polymer coated minicapsule or minisphere (2) encapsulating micronized nimodipine for delayed, sustained, controlled or targeted release. There are uncoated seamless minicapsules (3), the core of which comprises tacrolimus lipid-based formulation for immediate release and a controlled release polymer coated seamless minicapsule (4), the core of which comprises tacrolimus lipid-based formulation for delayed, sustained, controlled release or targeted release. The final dosage form may be a hard gelatin capsule (5).
35 Citations
93 Claims
-
1-17. -17. (canceled)
-
18. A modified release dosage product comprising:
-
a plurality of minicapsules or minispheres containing a calcium channel blocker; and a plurality of minicapsules or minispheres containing a calcineurin inhibitor. - View Dependent Claims (74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93)
-
-
19-73. -73. (canceled)
Specification